Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data.

However, the differences in positive C-MET overexpression among patients with other driver mutations in NSCLC did not reach statistical significance ( Figure 3(b) ).

also in 111,027 other papers

Patients with EGFR , ALK , KRAS , ROS1 , BRAF , and PIK3CA alterations exhibited an increasing trend in C-MET overexpression.

also in 63,971 other papers